Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist.

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist, according to a case series published online Jan.

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with ...

The suit – filed in a Massachusetts district court – claims that Paxlovid (nirmatrelvir and ritonavir) infringes its 11,358,953 patent which covers "compounds and pharmaceutically acceptable ...

Case series suggests longer nirmatrelvir/ritonavir treatments may benefit some individuals with long COVID, highlighting the need for further research into optimal usage. Study: Impact of extended ...